S&P Futures
4,080.50 -9.50 (-0.23%) Dow Futures
34,021.00 -135.00 (-0.40%) Nasdaq Futures
12,149.50 -2.50 (-0.02%) Russell 2000 Futures
1,935.50 -3.90 (-0.20%) Crude Oil
79.32 +0.45 (+0.57%) Gold
1,944.30 -1.00 (-0.05%)
Pre-Market:
Chart Events
Performance Outlook
| Previous Close | 5.57 |
| Open | 5.51 |
| Bid | 0.00 x 1200 |
| Ask | 5.75 x 1300 |
| Day's Range | 5.51 - 5.99 |
| 52 Week Range | 4.34 - 24.55 |
| Volume | |
| Avg. Volume | 4,273,321 |
| Market Cap | 460.971M |
| Beta (5Y Monthly) | -0.20 |
| PE Ratio (TTM) | 250.43 |
| EPS (TTM) | 0.02 |
| Earnings Date | Feb 07, 2023 - Feb 13, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | Apr 28, 2014 |
| 1y Target Est | 36.25 |
- GlobeNewswire
Veru to Report Fiscal 2023 First Quarter Financial Results on February 9, 2023
MIAMI, FL, Jan. 26, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral ARDS-related diseases and for oncology, today announced it will host a conference call and audio webcast on Thursday, February 9, 2023, at 8:00 a.m. ET to discuss its fiscal 2023 first quarter financial results and provide a business update. The audio webcast will be accessible under “Investor Kit” in the Investors page of the Compa
- Simply Wall St.
Those who invested in Veru (NASDAQ:VERU) five years ago are up 364%
Some Veru Inc. ( NASDAQ:VERU ) shareholders are probably rather concerned to see the share price fall 44% over the last...
- GlobeNewswire
Veru Announces Appointment of Dr. David D. Ho as Chairman of its Infectious Disease Scientific Advisory Board
MIAMI. FL, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral ARDS-related diseases and for oncology, today announced the appointment of David D. Ho, M.D., a trailblazer of infectious disease viral research and therapeutic development, as Chairman of its Scientific Advisory Board (SAB). “Today’s appointment of Dr. Ho as Chairman of Veru’s SAB illustrates our commitment to building a team of sc
